<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="122830">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02075372</url>
  </required_header>
  <id_info>
    <org_study_id>13/094L</org_study_id>
    <nct_id>NCT02075372</nct_id>
  </id_info>
  <brief_title>CrossBoss and Hybrid Registry on Coronary Chronic Total Occlusions</brief_title>
  <acronym>RECHARGE</acronym>
  <official_title>REgistry of CrossBoss and Hybrid Procedures in FrAnce, the NetheRlands, BelGium and UnitEd Kingdom</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hasselt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hasselt University</source>
  <oversight_info>
    <authority>Belgium: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The successful re-opening of a blocked coronary artery has a beneficial effect on the
      further clinical course (e.g. improvement of clinical symptoms, improved quality of life,
      increased heart function, etc.). However, some types of blockages are more difficult to open
      by means of percutaneous coronary intervention (PCI), a procedure which is commonly used for
      these kind of problems. This procedure makes use of a technique in which special wires,
      balloons, stents (metal or polymeric tube-like structures) and devices are utilized to
      re-open or revascularize a blockage in one of the blood vessels of the heart. This type of
      blockages are chronic total occlusions (CTO). CTOs have certain characteristics which impede
      the revascularization of the blood vessel.

      Nevertheless, remarkable progress has been achieved over the past few years in the area of
      CTO revascularization or CTO PCI. A large range of CTO dedicated materials, such as
      guidewires, guiding catheters, devices, balloons and stents, as well as different techniques
      have been developed. However, at present, reluctance to open CTOs still exists, due to the
      indications and outcomes of percutaneous revascularization as well as the technical
      difficulties which commonly arise during these interventional procedures. The presence of
      these difficulties results in suboptimal success rates worldwide (±70-80%), despite these
      many innovations.

      To increase these success rates and to make sure more interventional cardiologists will
      treat CTOs, a hybrid treatment algorithm has been developed with the materials (e.g.
      CrossBoss™ catheter; Bridgepoint Medical, Inc.) and techniques, currently already available.
      The main purpose of this study is to evaluate the efficacy and efficiency of this hybrid
      algorithm as well as validating the efficacy of one of the materials (CrossBoss™ catheter),
      used in this algorithm. To be able to do this, data concerning the patients' demographics,
      CTO characteristics, procedure and outcome will be collected in the form of a registry. This
      registry will be performed in several European centra (Belgium, the Netherlands, United
      Kingdom, France). Since the study will only collect data and no intervention is performed,
      this will be an observational study. At regular time points, the data will be checked for
      errors or inconsistencies. To do this, site visits will be performed at pre-defined times.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <target_duration>1 Day</target_duration>
  <primary_outcome>
    <measure>Outcome of CTO PCI procedure</measure>
    <time_frame>after 3 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Description: Success percentage of the hybrid algorithm and of those procedures in which CrossBoss™ and Stingray™ technologies are used (as a stand alone device or combined with other techniques) in CTO lesions according to the Japanese scoring system (J-CTO). Success is defined as successful revascularization, resulting in TIMI flow 3.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Outcome of PCI procedures in which CrossBoss™ technology is used (as a stand alone device)</measure>
    <time_frame>after 3 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Outcome (success/failure) of PCI procedures in which CrossBoss™ technology is used (as a stand alone device).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Outcome of PCI procedures in which CrossBoss™ technology is used (combined with other techniques).</measure>
    <time_frame>after 3 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Outcome (success/failure) of PCI procedures in which CrossBoss™ technology is used (combined with other techniques)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>up to month 1</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Complications (either CrossBoss™/Stingray™ related or not): Major Adverse Cardiac Events (MACE) during in-hospital stay (approximately 1-2 days) and at follow-up (first month after CTO PCI). MACE is common endpoint for death, Q-wave myocardial infarction (MI) (according to ESC guidelines), non Q-wave MI (according to ESC guidelines) and target vessel revascularization. Other complications include target vessel failure (i.e. applies when target vessel is occluded at follow-up (first month after CTO PCI) but no revascularization has been considered), tamponade, perforation, bleeding requiring transfusion/surgery, peri-procedural infarction ((N-)STEMI) (according to ESC guidelines) and loss of side-branches.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical status after PCI procedure</measure>
    <time_frame>up to month 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Record medical drug prescription (after CTO PCI) and clinical status during in-hospital stay and during follow-up (1 month).</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Chronic Total Occlusion of Coronary Artery</condition>
  <arm_group>
    <arm_group_label>Patients treated for CTO PCI</arm_group_label>
    <description>Patients diagnosed with the presence of one or more chronic total occlusions (CTOs) and who will receive treatment via percutaneous coronary intervention (PCI), which is standard medical practice for these types of lesions. This study will collect data on the patients' demographics, CTO characteristics, procedure and outcome. This will be done in the form of a registry</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Data registration</intervention_name>
    <description>Patients diagnosed with the presence of one or more chronic total occlusions (CTOs) and who will receive treatment via percutaneous coronary intervention (PCI), which is standard medical practice for these types of lesions. This study will collect data on the patients' demographics, CTO characteristics, procedure and outcome. This will be done in the form of a registry</description>
    <arm_group_label>Patients treated for CTO PCI</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients diagnosed with the presence of one or more chronic total occlusions (CTOs) and
        who will receive treatment via percutaneous coronary intervention (PCI)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject shows the presence of at least one coronary chronic total occlusion (CTO),
             either with or without the presence of one or more other diseased coronary arteries.
             This CTO must be located in a native coronary artery and have a visually estimated
             stenosis of 100%, corresponding with Thrombolysis in Myocardial Infarction (TIMI)
             flow 0. Following the operators judgment, this occlusion is present for more then 3
             months.

          -  Subject will be/is treated percutaneously for one or more CTOs via the hybrid
             techniques.

          -  Subject (or legal guardian) understands the study requirements and the treatment
             procedures and provides written informed consent before any study-specific procedures
             are performed.

          -  Subject is willing to comply with all protocol-required follow-up evaluation (patient
             will be followed during 1 month after PCI procedure to assess any complications and
             clinical status).

        Exclusion Criteria:

          -  The occlusion is considered to be less than 3 months present.

          -  Subject is treated via PCI without application of the hybrid algorithm and/or use of
             the CrossBoss™ and Stingray™ technology (Bridgepoint Medical, Inc.).

          -  Subject is participating in another investigational clinical trial that may cause
             non-compliance with the protocol or confound data interpretation.

          -  Subject intends to participate in another investigational clinical trial that may
             cause non-compliance with the protocol or confound data interpretation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jo Dens, prof. dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ziekenhuis Oost-Limburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Joren Maeremans, MSc</last_name>
    <role>Study Chair</role>
    <affiliation>Ziekenhuis Oost-Limburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jo Dens, prof. dr.</last_name>
    <email>jo.dens@zol.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joren Maeremans, MSc</last_name>
    <email>maeremansjoren@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussel</city>
        <state>Limburg</state>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Kayaert, MD</last_name>
      <email>peter.kayaert@uzbrussel.be</email>
    </contact>
    <investigator>
      <last_name>Peter Kayaert, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ziekenhuis Oost-Limburg</name>
      <address>
        <city>Genk</city>
        <state>Limburg</state>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jo Dens, prof. dr.</last_name>
      <email>jo.dens@zol.be</email>
    </contact>
    <contact_backup>
      <last_name>Joren Maeremans, MSc</last_name>
      <email>maeremansjoren@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jo Dens, prof.dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joren Maeremans, MSc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hasselt University</name>
      <address>
        <city>Hasselt</city>
        <state>Limburg</state>
        <zip>3500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jo Dens, prof.dr.</last_name>
      <email>jo.dens@zol.be</email>
    </contact>
    <investigator>
      <last_name>Jo Dens, prof. dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier Mutualiste (GHM)</name>
      <address>
        <city>Grenoble</city>
        <zip>38000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Faurie, MD</last_name>
      <email>faurieb@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Benjamin Faurie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique de Marignane</name>
      <address>
        <city>Marignane</city>
        <zip>13700</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre Avran, MD</last_name>
      <email>a.bohor@wanadoo.fr</email>
    </contact>
    <investigator>
      <last_name>Alexandre Avran, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nouvelles Cliniques Nantaises (NCN)</name>
      <address>
        <city>Nantes</city>
        <zip>44277</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erwan Bressollette, MD</last_name>
      <email>erwan.bressollette@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Erwan Bressollette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord - CHU de St Etienne</name>
      <address>
        <city>Saint-Priest en Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karl Isaaz, MD</last_name>
      <email>isaaz@univ-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Karl Isaaz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Onze-Lieve-Vrouwe Gasthuis (OLVG)</name>
      <address>
        <city>Amsterdam</city>
        <zip>1091 AC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert-Jan van der Schaaf, MD</last_name>
      <email>vanderschaaf.olvg@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Robert-Jan van der Schaaf, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catharina Ziekenhuis</name>
      <address>
        <city>Eindhoven</city>
        <zip>5623</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacques Koolen, MD</last_name>
      <email>jacques.koolen@catharinaziekenhuis.nl</email>
    </contact>
    <contact_backup>
      <last_name>Inge Wijnbergen, MD</last_name>
      <email>inge.wijnbergen@catharinaziekenhuis.nl</email>
    </contact_backup>
    <investigator>
      <last_name>Jacques Koolen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Inge Wijnbergen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert-Jan van Geuns, MD</last_name>
      <email>r.vangeuns@erasmusmc.nl</email>
    </contact>
    <investigator>
      <last_name>Robert-Jan van Geuns, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht (UMCU)</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierfrancesco Agostoni, MD</last_name>
      <email>p.agostoni@umcutrecht.nl</email>
    </contact>
    <investigator>
      <last_name>Pierfrancesco Agostoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Basildon University Hospital</name>
      <address>
        <city>Basildon</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paul Kelly, MD</last_name>
      <email>paul.kelly@btuh.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Paul Kelly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Belfast City Hospital</name>
      <address>
        <city>Belfast</city>
        <zip>BT9 7AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Simon Walsh, MD</last_name>
      <email>simon.j.walsh@btinternet.com</email>
    </contact>
    <contact_backup>
      <last_name>Colm Hanratty, MD</last_name>
      <email>cghanratty@hotmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Simon Walsh, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Colm Hanratty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of Bristol</name>
      <address>
        <city>Bristol</city>
        <zip>BS1 2LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julian Strange, MD</last_name>
      <email>julian.strange@uhbristol.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Julian Strange, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ninewells Hospital</name>
      <address>
        <city>Dundee</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Irving, MD</last_name>
      <phone>+44 7775 615462</phone>
      <email>johnirving@nhs.net</email>
    </contact>
    <investigator>
      <last_name>John Irving, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <zip>EH16 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>James Spratt, MD</last_name>
      <email>jamesspratt@hotmail.co.uk</email>
    </contact>
    <investigator>
      <last_name>James Spratt, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Golden Jubilee Hospital</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Margaret McEntegart, MD</last_name>
      <email>Margaret.mcentegart@gjnh.scot.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Keith Oldroyd, MD</last_name>
      <email>Keith.oldroyd@nhs.net</email>
    </contact_backup>
    <investigator>
      <last_name>Keith Oldroyd, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Margaret McEntegart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kings College London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jonathan Hill, MD</last_name>
      <email>jmhill@nhs.net</email>
    </contact>
    <investigator>
      <last_name>Jonathan Hill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>London Chest Hospital</name>
      <address>
        <city>London</city>
        <zip>E2 9JX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elliott Smith, MD</last_name>
      <email>elliot.smith@bartshealth.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Elliott Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Freeman Hospital</name>
      <address>
        <city>Newcastle</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alan Bagnall, MD</last_name>
      <phone>+44 7590643481</phone>
      <email>alan.bagnall@nuth.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Mohaned Egred, MD</last_name>
      <phone>+44 7717 475131</phone>
      <email>mohaned.egred@nuth.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Alan Bagnall, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohaned Egred, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital</name>
      <address>
        <city>Nottingham</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alun Harcombe, MD</last_name>
      <email>alun.harcombe@nuh.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>William Smith, MD</last_name>
      <email>william.smith@nuh.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Alun Harcombe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>France</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 28, 2014</lastchanged_date>
  <firstreceived_date>December 16, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hasselt University</investigator_affiliation>
    <investigator_full_name>​prof. dr. Jo Dens</investigator_full_name>
    <investigator_title>prof. dr.</investigator_title>
  </responsible_party>
  <keyword>Chronic Total Occlusion of Coronary Artery</keyword>
  <keyword>Percutaneous Coronary Intervention</keyword>
  <keyword>Hybrid</keyword>
  <keyword>Angioplasty</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
